Starting November 15, Rodrigo Leite de Oliveira (PharmD, PhD) will be the new Cancer Center Amsterdam and Amsterdam UMC CRISPR Platform manager.

Rodrigo is a former EMBO fellow who has been working on functional cancer genomics with René Bernards (The Netherlands Cancer Institute). Rodrigo will be supporting different CRISPR projects, such as improving precise gene editing techniques, and designing dedicated human and mouse CRISPR gRNA libraries for rapid screening. As soon as the COVID-19 situation permits, you will find Rodrigo either at location AMC (Louis Vermeulen Lab) or location VUmc (Oncogenetics, Rob Wolthuis Lab). Rodrigo’s appointment is co-financed by the CCA and the Amsterdam UMC Innovation Fund.

Visit the CRISPR platform website: www.crispr-platform.nl.

Questions for CRISPR platform support can be directed to crispr@amsterdamumc.nl.

Portrait of Rodrigo Leite de Oliveira
Portrait of Rodrigo Leite de Oliveira

About CRISPR

The CRISPR technique enables us to make precise changes to the DNA. This recent technology has enormous potential, for example, treatment-resistant cancer cells can be made susceptible to therapies. In order to take full advantage of possible applications of this new technique, we have recruited an expert in the field of CRISPR. With the launch of an online platform containing relevant up-to-date information involving CRISPR, professionals can stay informed, ask questions or get help setting up studies. The UMC CRISPR Platform  has already proven successful: several grants utilizing CRISPR technology have recently been awarded. In addition, courses and seminars have been developed to provide information and education about CRISPR applications.